Yajun Xu has more than 20 years’ experience in drug discovery and development. Yajun is currently President of Shangpharma Investment Group. Yajun is also co-founder of Epimab Biotherapeutics (a biotech company based in China), Board of Director for Abcuro therapeutics (a biotech company), advisor for ZAI Lab Limited (a biopharma, Shanghai based) and advisor for Hotspot Therapeutics (a biotech company).
Yajun was previously Sr. Vice President of corporate development of Shangpharma. Yajun was the founder, Vice President of biology and pre-clinical service platform for Shanghai ChemPartner (a CRO company based in China) from 2007 to 2014. Prior to Chempartner, Yajun was director of research at Millennium Pharmaceutical Inc., where she worked for 6 years and managed small molecule kinase inhibitor portfolios for inflammation/immunology indication.
Previously, Yajun was a senior scientist at BASF Bioresearch Corp. (now Abbott Bioresearch Corp.) for 5 years to support drug discovery programs in both inflammation and oncology. Yajun received her Ph.D. in Biochemistry at Brandeis University in 1992 and postdoctoral training at Harvard School of Public Health in department of Cell Biology and Molecular Toxicology. She received MS and BS degrees in Chemistry from Beijing University of Chemical Technology in China in 1986 and 1983.